Anavex Life Sciences Corp (AVXL)

[blu_1]

I still think you got it wrong. Read this paragraph taken from the linked article. It clearly says that the 5 week Part A portion was "...followed by a 52 week, open label, extension trial...":

The 5-week, randomized, dose-finding, crossover trial started one group of patients on 30 or 50 mg/day oral ANAVEX 2-73 for 11 days after an initial 2-day, single-dose, pharmacokinetic analysis, followed by an 11-day washout period, and then 11 days of 3 mg/day or 5 mg/day intravenously. A second group first received 11 days of 3 mg/day or 5 mg/day ANAVEX 2-73 intravenously after an initial 2-day, single-dose, pharmacokinetic analysis, followed by an 11-day washout period, and then 30 or 50 mg/day oral ANAVEX 2-73 for 11 days. This was followed by a 52-week, open-label, extension trial of 10-50 mg/day orally, titrating each patient to the maximum tolerated dose. The extension phase was originally planned to last 6 months, but patients and caregivers wanted to continue on the medication, so the company extended it to 12 months. It is ongoing.

http://www.mdedge.com/clinicalneurologynews/article/120066/alzheimers-cognition/sigma-1-agonist-presses-forward-after